Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Revenue (2016 - 2025)

Historic Revenue for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $3.7 million.

  • Lineage Cell Therapeutics' Revenue fell 259.33% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.8 million, marking a year-over-year increase of 2405.09%. This contributed to the annual value of $9.5 million for FY2024, which is 619.34% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Revenue of $3.7 million as of Q3 2025, which was down 259.33% from $2.8 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Revenue high stood at $50.0 million for Q4 2021, and its period low was $391000.0 during Q1 2021.
  • In the last 5 years, Lineage Cell Therapeutics' Revenue had a median value of $2.4 million in 2023 and averaged $5.0 million.
  • Its Revenue has fluctuated over the past 5 years, first soared by 1398450.7% in 2021, then plummeted by 9617.0% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Revenue stood at $50.0 million in 2021, then plummeted by 96.17% to $1.9 million in 2022, then increased by 9.03% to $2.1 million in 2023, then soared by 37.36% to $2.9 million in 2024, then rose by 28.35% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $2.8 million for Q2 2025, and $1.5 million during Q1 2025.